← All indications
Sleep Initiation and Maintenance Disorders
Disorders characterized by impairment of the ability to initiate or maintain sleep. This may occur as a primary disorder or in association with another medical or psychiatric condition.
Subtype terms (1)
More specific conditions that are subtypes of Sleep Initiation and Maintenance Disorders in the MeSH hierarchy.
- Insomnia, Fatal Familial
1 drug approved
Drugs by status
Approved for this indication (35)
- daridorexant
- betaine
- diphenhydramine
- suvorexant
- doxylamine
- estazolam
- flurazepam
- zopiclone
- lemborexant
- levomepromazine
- ramelteon
- sihogayonggolmoryu tang
- temazepam
- triazolam
- zaleplon
- zolpidem
- mirtazapine
- chloral hydrate
- barbital
- trichlorobutanol
- ethchlorvynol
- butabarbital
- ethinamate
- glutethimide
- methaqualone
- methyprylon
- quazepam
- secobarbital
- triclofos
- amobarbital
- +5 more
Phase 4 trials (24)
Phase 3 trials (25)
Phase 2 trials (36)
- gsk649868
- adipiplon
- Casopitant
- nabilone
- chamomile
- cyclobenzaprine
- vofopitant
- evt 201
- filorexant
- sodium oxybate
- ly2624803
- nelotanserin
- neurexan
- piromelatine
- cannabis
- suan tzao ren tang
- tetrahydrocannabinol
- tian wang bu xin dan
- paliperidone
- v117957
- vestipitant
- human fecal microbiota
- valerian root extract
- varenicline
- atagabalin
- pruvanserin
- sodium chloride
- cherry
- ferrous sulfate
- ts-142
- +6 more
Phase 1 trials (8)
Other trials (41)
- maltodextrin
- aminolevulinic acid
- cocoa bean
- methylphenidate
- ginger
- huanglian-jie-du-tang
- esketamine
- magnesium oxide
- prazosin
- lidocaine
- risperidone
- thiamine
- coffee
- cyclamax
- iqp-ao-101
- lactobacillus plantarum
- magnesium glycinate
- spinach
- lexipro
- rhizoma atractylodis macrocephalae
- midazolam
- fatty acid
- gardenia jasminoides ellis
- pregabalin
- artemisia
- salvia
- broccoli
- phosphate
- pyrithyldione
- heptabarbital
- +11 more
Organizations
Organization Involved with Phase 4 Indications (70)
- Eisai
- Cephalon
- Shire
- Astellas
- Pfizer
- Sanofi
- Sanofi-Synthelabo
- GlaxoSmithKline
- MedVadis Research Corporation
- National Institutes of Health (NIH)
- National Cancer Institute (NCI)
- National Institute of Mental Health (NIMH)
- National Institute on Aging (NIA)
- Associação Fundo de Incentivo à Pesquisa
- National Jewish Health
- University of Pennsylvania
- University of Arizona
- University of Pittsburgh
- Augusta University
- Baylor University
- Brown University
- Children's Specialized Hospital
- China Academy of Chinese Medical Sciences
- Harvard University
- Duke University
- Henry Ford Health System
- Howard University
- Institute for Advanced Medical Research, Alpharetta, GA
- Jichi Medical University
- Lehigh Center for Clinical Research
- +40 more
Organization Involved with Phase 3 Indications (47)
- 9305-9954 Quebec Inc
- Ache Laboratorios Farmaceuticos S.A.
- Purdue Pharmaceuticals
- Biolab Sanus Farmaceutica
- Eurofarma Laboratorios S.A.
- Kuhnil Pharmaceutical Co., Ltd.
- Midnight Pharma, LLC
- Neurim Pharmaceuticals Ltd.
- Neurocrine Biosciences
- Parexel
- Sage Therapeutics
- Transcept Pharmaceuticals
- Boehringer Ingelheim
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- United States Army
- Dankook University
- University of Washington
- Kyung Hee University
- Northwestern University
- Seoul National University
- University of Toronto
- University of Brasilia
- University of Cincinnati
- University of Ulsan
- University of Utah
- University of Minnesota
- Allergisa Pesquisa Dermato-Cosmetica LTDA
- Azidus
- Clinilabs
- Konkuk University
- +17 more
Organization Involved with Phase 2 Indications (44)
- Actelion
- Jazz Pharmaceuticals
- Bausch Health Companies
- Arena Pharmaceuticals
- Evotec
- INC Research
- Intec Pharma Ltd.
- Neurogen Corporation
- Eusol
- Somnus Therapeutics, Inc.
- Taisho Pharmaceutical
- The EMMES Corporation
- National Center for Complementary and Integrative Health (NCCIH)
- National Institute of Nursing Research (NINR)
- Case Western Reserve University
- Chung Shan Medical University
- Gillette Children's Specialty Healthcare
- I.M. Sechenov First Moscow State Medical University
- McGill University
- Melbourne Health
- New York University
- University of Michigan
- State University of New York
- Vince & Associates
- Algorithme Pharma Inc
- Broward Research Group
- University of Montreal
- Forenap Pharma
- State University of New York, Syracuse
- Neurotrials Inc.
- +14 more
Organization Involved with Phase 1 Indications (10)
Organization Involved with Other Experimental Indications (25)
- AstraZeneca
- InQpharm Group
- Teva
- Verifomics LLC
- Roxane Laboratories
- National Center for Research Resources (NCRR)
- National Institute on Alcohol Abuse and Alcoholism (NIAAA)
- Persee Medica
- ARCIM Institute
- Chulalongkorn University
- Johns Hopkins University
- Mclean Hospital
- Ryerson University
- University of Hawaii
- University of Vermont
- Jiao Tong University
- analyze & realize GmbH
- Novum Pharmaceutical Research Services
- Hebrew University
- University of Texas at Houston
- Chengdu University of Traditional Chinese Medicines
- Pennsylvania State University
- PRACS
- KhonKaen University
- SBI ALApromo Co., Ltd